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Abstract 
Huntington’s disease (HD) (OMIM 143100) is caused by an expanded CAG repeat tract in the 
HTT gene. The inherited CAG length is known to expand further in somatic and germline 
cells in HD subjects. Age at onset of the disease is inversely correlated with the inherited 
CAG length, but is further modulated by a series of genetic modifiers which are most likely 
to act on the CAG repeat in HTT that permit it to further expand. Longer repeats are more 
prone to expansions, and this expansion is age dependent and tissue-specific. Given that the 
inherited tract expands through life and most subjects develop disease in mid-life, this 
implies that in cells that degenerate, the CAG length is likely to be longer than the inherited 
length. These findings suggest two thresholds – the inherited CAG length which permits 
further expansion, and the intracellular pathogenic threshold, above which cells become 
dysfunctional and die. This two-step mechanism has been previously proposed and 
modelled mathematically to give an intracellular pathogenic threshold at a tract length of 
115 CAG (95% confidence intervals 70-165 CAG). Empirically, the intracellular pathogenic 
threshold is difficult to determine. Clues from studies of people and models of HD, and from 
other diseases caused by expanded repeat tracts, place this threshold between 60-100 CAG, 
most likely towards the upper part of that range. We assess this evidence and discuss how 
the intracellular pathogenic threshold in manifest disease might be better determined. 
Knowing the cellular pathogenic threshold would be informative for both understanding the 
mechanism in HD and deploying treatments.  
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Background 
Huntington’s disease (HD) is one of >50 diseases caused by expanded short tandem repeats 
[1,2]. In those diseases where the repeat is coding, as in HD, the repeat unit is usually CAG 
and this is translated to a homopolymeric glutamine tract in the encoded protein. There are 
nine such diseases, often referred to collectively as the polyglutamine diseases. The sections 
of these proteins containing expanded glutamine form cellular aggregates [3]. The 
polyglutamine diseases have disease-causing expansion lengths that are much shorter than 
those in diseases where the repeats causing the expansion are not translated [4,5], implying 
a possible constraint on length at the level of the protein. While somatic expansion is critical 
in reaching the critical intracellular pathogenic CAG length threshold, the subsequent events 
leading to cell dysfunction and death have not been conclusively defined (Figure 1). Much 
attention has focused on the expanded glutamine tract in the protein but it has never been 
conclusively proven that this elicits toxicity in cells in human disease, and the genetic 
evidence implicates CAG length rather than polyglutamine length as critical in HD 
pathogenesis [6–8]. Other potential pathogenic mechanisms that cannot be precluded  
include RNA-based toxicity as in myotonic dystrophy (OMIM 160900) [9], RAN translation 
[10] and aberrant exon 1 splicing [11]: all of these mechanisms would also be exacerbated 
by somatic expansion of the repeat in individual cells. Recent evidence of 
neurodevelopmental effects in Huntington’s disease [12], and early phenotypes in 
peripheral blood mononuclear cells [13,14], may indicate other pathways impacted by the 
unexpanded CAG length, but the genetic evidence in HD subjects very clearly points to 
somatic expansion as likely to be important in disease manifestation.   
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In HD, age at onset of disease is largely determined by the length of the CAG tract [15–17]. 
More recently, however, age at onset has been shown to be modulated by a series of 
genetic modifiers whose discovery has revolutionised the way we think about HD 
pathogenesis [7,18,19] (Hong et al., this issue). Two types of genetic modifier revealed so far 
have provided evidence that has made us rethink our notions of HD pathogenesis. First, 
some of the encoded proteins translated from these modifiers act directly on DNA and are 
most likely to exert their effect at the level of the mutated expanded DNA, through 
modulating the length of the CAG tract in both somatic and germline cells [18–20](Hong et 
al., this issue), and indeed, this has been shown experimentally in cell culture [21,22]. 
Second, the exact sequence at the HTT CAG locus exerts a strong influence on age at onset 
of disease [6–8]. The length of the uninterrupted CAG tract correlates most closely with age 
at onset of disease and any interrupting bases that disrupt the continuous repeated 
sequence delay age at onset. Not all of the difference in onset age appears to be 
determined by uninterrupted CAG length at the HTT locus, in particular, having no CAA 
interruptions appears to hasten onset, while the effect of having more than one CAA at the 
3’ end of the repeat tract is unclear [6,7]. Together, these findings refocus attention on the 
causative repeat expansion at the level of the DNA, rather than the expanded glutamine 
tract in the mutant huntingtin protein that is translated from it. 
 
A two-stage hypothesis of disease pathogenesis 
We know that further expansion of the HTT CAG tract occurs in the brain cells of HD 
subjects [23–25], that longer CAG tracts are more likely to expand [26,27], and that the 
greater the expansion in brain the earlier the onset of disease [28]. These observations in 
humans validate previous findings in mice and provide a link between genetic data from 
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human subjects and disease models of repeat instability [18,29,30] (Hong et al., Wheeler 
and Dion, this issue). These genetic data imply that at the point at which the CAG tract 
elicits toxicity in susceptible cells, which we refer to as the intracellular pathogenic CAG 
length, it is likely to be longer than the diagnostic disease-causing length of 36 CAG or more 
measured in the subjects’ blood.  It is plausible that the inherited disease-causing threshold 
of 36 CAG in HD is the threshold beyond which further CAG repeat expansions are 
permissible in susceptible somatic cells (Figure 1). It is also possible that there is a vicious 
cycle where alterations in DNA damage and repair exacerbate somatic expansion of the 
repeat [31]. So how can we define the intracellular pathogenic repeat length in such cells? 
Or at least the length that is pathogenic in a high enough proportion of the appropriate cell 
types to cause disease symptoms? This important information is lacking: defining such a 
threshold would be useful in clinical prognosis and clinical trials. A version of this interesting 
idea has been proposed previously by Kaplan and colleagues [32]. They postulated a 
mechanism where onset and progression of the disease are determined by the rate of 
expansion of the repeat tract in specific cells in the subject, and that the disease manifests 
only when the repeat tract has expanded beyond a certain threshold in a sufficient number 
of these cells. Progression is then determined by the rate at which more cells cross the 
pathogenic threshold for repeat length. The expansion rate and pathogenic threshold are 
estimated from clinical data (onset and repeat length of the inherited allele).  The model 
assumes that the expansion rate is linear with respect to repeat length above an initial 
threshold, determined from clinical data (37 for HD). The assumption of linear expansion 
rate has not been confirmed experimentally, although Kaplan et al. found that the onset 
predictions given by their model appeared to fit observed data for a number of repeat 
disorders, including HD, the polyglutamine tract mediated spinocerebellar ataxias (SCAs), 
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myotonic dystrophy 1 (DM1, OMIM 160900) and Friedreich’s ataxia (FA, OMIM 229300).  
This model also predicts that earlier onset and longer CAG are correlated with faster 
progression, consistent with recent clinical observations [19,33].  It may also explain why 
pre-clinical symptoms are evident up to 15 years prior to disease onset [34–37]. This 
premanifest period reflects a proportion of cells that have somatic expansion which induces 
neuronal dysfunction, but too few to manifest overt clinical symptoms (Figure 2). It is also 
likely that with a slow degeneration of neurons during this period, there is functional 
compensation in the CNS [38,39]. The new genetic evidence makes this a compelling 
hypothesis in the pathogenesis of HD and other repeat disorders. This prescient paper has 
notably only been cited eleven times in 13 years [32].  
 
A     
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B                                                                              
 
Figure 1 A model for the pathogenic threshold in HD. A) HD pathogenesis is largely 
determined by an expanded cytosine-adenine-guanine (CAG) trinucleotide repeat within 
exon 1 of the huntingtin (HTT) gene, which is transcribed into an expanded polyglutamine 
tract in the corresponding HTT protein. Wild-type HTT possesses 5-35 CAG repeats (non-
expanded HTT gene), and can undergo expansion into the disease rage in the germline to 
create apparent de novo HD subjects, but ≥36+ repeats is associated with a significantly 
increased risk of developing HD (expanded HTT gene). B) An expanded HTT allele with 36 or 
more repeats is unstable and licenced to further expand in cells over the lifespan of the HD 
at-risk individual. HD symptoms would manifest and progress as increasing numbers of 
disease-relevant cells undergo somatic expansion beyond an unknown intracellular 
pathogenic threshold that renders the gene toxic in those cells. Figures created using 
BioRender.com. Figure 1A adapted from figure by National Institute of General Medical 
Sciences, National Institutes of Health.   
 
The in silico modelling of Kaplan et al. predicted that the intracellular pathogenic CAG length 
threshold in HD was 115 CAG. However, the confidence intervals for this threshold are wide 
(95% CI 93-170 CAG), possibly due to the model being fitted to a relatively small sample 
(n=336). Do we have any evidence that would allow us to determine whether 115 CAG is a 
reasonable estimate of the threshold, or to refine that wide confidence interval? This is 
critical, as under this scenario, the period of an HD at-risk subject’s life before such a 
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threshold is reached is a window of opportunity for therapies that address the expansion of 
the repeat (Figure 2). It is potentially a large window as expansion is likely to occur 
throughout life [25,40–42] and at-risk subjects remain largely indistinguishable from their 
non-HD at-risk peers for a substantial period of that time [37].  
Figure 2 Potential relationship of CAG tract expansion and clinical Huntington’s disease 
events. The premanifest period of the disease may reflect the presence of a proportion of 
disease-relevant cells with sufficient somatic expansion to induce neuronal dysfunction, but 
too few to manifest overt clinical symptoms. Premanifest HD includes a presymptomatic 
period where no signs or symptoms are present, and prodromal HD, characterised by the 
onset of subtle signs and symptoms, which may be the result of the HTT CAG length 
expanding beyond an unknown pathogenic threshold in increasing numbers of disease-
relevant cells. Manifest HD – characterised by chorea and gradual worsening of motor and 
cognitive difficulties – may then arise once a significant number of disease-relevant cells 
have passed this threshold. Somatic expansion in susceptible cell populations is likely to be 
occurring throughout the premanifest and prodromal stages of disease as indicated by the 
hypothetical dashed line, although the actual trajectory of this expansion will depend on the 
inherited repeat length and is likely to differ in different cell types. Therefore the 
relationship between the trajectory of somatic expansion and clinical phenotypes is 
currently hypothetical. Figure adapted from Ross et al. 2014 and Bates et al. 2015 and 
created using BioRender.com. 
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There are some potential clues to the intracellular pathogenic threshold. We might be able 
to improve the definition of the edge of the pathogenic thresholds using data from mouse 
models. In mouse models the repeat is normally expanded to 100 CAG or more in order to 
induce a disease-like phenotype in the short-lived mouse [43,44]. Even in the presence of 
tracts of over 100 CAG in their Htt gene, mice may only develop subtle phenotypes late in 
their lifespan. Other diseases where a CAG tract is translated to a polyglutamine tract may 
also offer some clues about thresholds for intracellular CAG toxicity [4,45–47]. Possible 
inferences from these sources of evidence are discussed below. 
 
Evidence from HD animal models  
There are many animal models of HD generated in a number of different ways (Table 1). 
They can be divided into those expressing transgenes with a truncated section of human 
HTT carrying the CAG tract, or full length human HTT, and those with long CAG tracts 
replacing mouse Htt in one way or another [3,43,44,48]. Instability of the repeat sequence 
has been seen in many of the mouse models and was noted in the first HD models ever 
reported, the R6 series [49,50].  
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Table 1 Animal models of Huntington’s disease with up to 100 CAG repeats  
 
Animal model Construct Promoter PolyQ repeat 
length 
Pure repeat 
length/interruptions 
Phenotype Somatic expansion? References 
YAC46 
(mouse) 
FL human HTT gene 
within a YAC 
HTT Q46 46 mixed CAA/CAG Increased NMDA-induced Ca+ 
response, but no behavioural or 
cognitive phenotype 
Not reported [51–53] 
HD46 N-terminal 3 kb of 
human HTT cDNA 
Rat NSE Q46 (CAG)n(CAA)(CAG) Increased incidence of clasping, 
abnormal gait and abnormal activity- 
though time-points are not clear. HTT 
inclusions in cortex and striatum. 
Not reported [54] 
 
 
HD48 FL human HTT  CMV Q48 (CAG)n(CAA)(CAG) Limb clasping from 8-24 weeks weeks, 
hyperactivity from 20 weeks, reduced 
exploration from 24 weeks. Neuronal 
loss and fibrillary astrocytosis in the 
striata. HTT aggregates. 
Not reported [55] 
HdhQ50 Chimeric human 
exon 1/ mouse Htt 
Htt Q50 (CAG)48(CAA)(CAG) No behavioural or neuropathological 
changes observed at 6 months of age 
Not reported [56,57] 
HDQ50 CAG-only tract 
knocked into 
mouse exon 1 
Htt Q52 (CAG)50(CAA)(CAG) No behavioural or pathological 
changes observed. 
Not reported but germline 
expansion is present. The 
allelic line HDQ150 has 
somatic expansion. 
[24,58,59] 
 
Tg51 (rat) 1962 bp rat Htt 
cDNA fragment 
Htt Q51 Not clear Reduced anxiety from 2 months, 
impaired coordination from 10 
months, nuclear inclusions from 12 
months 
Not reported [60] 
CAG71 Chimeric human 
exon 1/ mouse Htt 
Htt Q71 (CAG)71 (R42) Arginine 
residue at position 42 
No behavioural abnormalities. Not reported [61,62] 
YAC72 
(mouse) 
Full length human 
HTT gene within a 
yeast artificial 
chromosome 
HTT Q72 (CAG)n(CAA)(CAG) Circling and foot-clasping from 9 
months, hyperactivity at 7 months, HTT 
aggregates and striatal degeneration 
from 12 months 
Not reported [51,53,63] 
Hdh6/Q72 Chimeric human 
exon 1/ mouse Htt 
Htt Q72 (CAG)n(CAA)(CAG) Hyperaggressive behaviour from 3 
months. No neuropathological 
changes. 
Yes. Multiple tissues. 
Expansion bias in striatum 
where >80% of cells  
showed expansions 
greater than +5 CAG. 
[64] 
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Htt-Q79 Chimeric human 
exon 1/ mouse Htt 
Htt Q77 (CAG)n(CAA)(CAG) Aggressive behaviour. Reactive gliosis 
from 40 weeks, nuclear inclusions in 
the striatum from 80 weeks. 
Yes. Multiple tissues 
(brain, liver, kidney and 
stomach) 
[65,66] 
Hdh4/Q80 Chimeric human 
exon 1/ mouse Htt 
Htt Q80 (CAG)n(CAA)(CAG) Hyperaggressive behaviour from 3 
months. Diffuse nuclear staining in the 
striatum from 17 weeks, HTT 
aggregates from 48 weeks. 
Yes, high levels observed 
in the striatum at 24 
months. Expansions were 
also observed in the 
cortex, cerebellum, 
hippocampus, hindbrain, 
spinal cord, olfactory bulb, 
kidney and eye 
[64,67–69]  
 
N171-82Q N-terminal 171 
amino acids of 
human HTT cDNA 
Prp Q82 (CAG)n(CAA)(CAG) Motor deficit from 5 months, HTT 
nuclear inclusions 
Not reported [70] 
N586-82Q N-terminal 586 
amino acids of 
human HTT cDNA 
Prp Q82 (CAG)n(CAA)(CAG) Rotarod deficit from 4 months, 
hyperactivity from 5 months, HTT 
aggregates and cognitive impairment 
from 8 months 
Not reported [71] 
HD89 FL human HTT CMV Q89 (CAG)n(CAA)(CAG) Limb clasping from 8 weeks, 
hyperactivity from 20 weeks, less 
exploration from 24 weeks. Neuronal 
loss and fibrillary astrocytosis in the 
striata. 
Not reported [55] 
R6/1-89Q Human HTT exon 1 HTT Q89 (CAG)n(CAA)(CAG) Clasping behaviour from 24 weeks, 
diffuse nuclear staining in cerebral 
cortex and hippocampus from 11 
weeks, body weight loss from 28 
weeks 
Yes. Expansions in motor 
cortex and hippocampus 
from 9 weeks. 
[72] 
 
HdhQ92 
 
Chimeric human 
exon 1/mouse Htt 
Htt Q92 (CAG)n(CAA)(CAG) Cognitive deficits from 4 months, mild 
motor deficit and HTT aggregates from 
6 months, striatal cell loss from 8 
months 
Yes, in striatum and liver  [57] 
CAG94 Chimeric human 
exon 1/mouse Htt 
Htt Q94 (CAG)94 (R42) 
Arginine residue at position 
42 
Increased sensitivity to NMDA from 7 
weeks. Increased rearing from 9 
weeks, decreased motor and 
exploratory activity from 18 weeks 
Not reported [61,62] 
 
Hu97/18 
(mouse) 
Two full human HTT 
alleles, one mutant 
and one wild type 
HTT Q97 (CAG)n(CAA)(CAG) Learning and motor deficit from 2 
months, progressive cognitive deficits 
from 6 months, reduced cortical and 
striatal volume from 12 months 
Not reported [73,74] 
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BAC HD (mouse) FL human HTT  HTT Q97 97 mixed CAA/CAG Motor deficit at 2 months significant 
by 6 months, no HTT aggregates  
No [75–77] 
BAC HD (rat) FL human HTT  HTT Q97 97 mixed CAA/CAG Motor deficit from 2 months, 
hypoactivity from 4 months, learning 
deficit from 6 months 
No [78–80] 
HD100 N-terminal 3 kb of 
human HTT cDNA 
Rat NSE Q100 (CAG)98(CAA)(CAG) Rotarod impairment, clasping, 
abnormal gait from 13-78 weeks. HTT 
inclusions from 13 weeks 
Not reported [54]  
HDQ50 CAG tract knocked 
into mouse exon 1 
Htt Q100 (CAG)100(CAA)(CAG) No behavioural or pathological 
changes observed. 
Not reported but germline 
expansion is present. The 
allelic line HDQ150 has 
somatic expansion. 
[24,58,59] 
 
NSE = neuron-specific enolase; CMV = cytomegalovirus; PrP = prion gene promoter. Not reported means no data were available. No means 
somatic expansion was investigated and not seen.
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Although there are multiple rodent models which have been deployed to help us 
understand the biology of HD and begin the search for therapies, many are limited in their 
ability to inform us of the effects of genetic modifiers of disease, as they often present with 
repeats well above the presumed intracellular pathogenic threshold and a severe 
phenotype. The most useful are those with relatively short repeats (Table 1) though they 
have differences in their genetic manipulations that make straightforward inferences about 
the threshold for intracellular pathogenesis complex. They all have either full length human 
HTT transgenes or human exon 1 replacing mouse exon 1. This may lead to differences in 
transcription and translation compared with humans.  Often several copies of a transgene 
are present in a genome and RNA and protein expression levels are variable. While the 
human disease is completely dominant and expression levels of HTT seem irrelevant to 
disease manifestation and course [81], that is not true in all animal models where 
expression levels do appear to influence phenotype, as discussed below. Perhaps most 
challenging is that in many of these models a human HTT gene has been used with a long 
pure CAG tract. This will almost invariably lead to somatic expansion thus the intracellular 
pathogenic threshold we are interested in is a moving target – it will have expanded in 
individual cells from the inherited or engineered repeat length but by an unknown amount. 
Finally, somatic expansion itself can be transcriptionally mediated [82–84], meaning that 
alterations in transcription across an expansion prone-repeat may themselves alter levels of 
expansion. 
 
An added complication is that very long repeats appear less pathogenic than shorter 
disease-causing repeats, and more prone to contraction than expansion [85], though it is 
not clear why [86,87]. The earliest onset and most deleterious phenotypes are seen around 
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150 CAG with longer CAG tracts giving later phenotypic changes [86–88] though it should be 
noted that in mice with an inherited ~150 CAG there is also somatic expansion and the 
repeat length in the susceptible cells is likely to be longer than 150 CAG. Very long repeat 
tracts form unusual DNA structures [2] that can inhibit transcription or translation of HTT 
[2,86], though there is evidence that the somatically expanded CAG tracts in DNA are 
transcribed and translated into expanded polyglutamine-containing mutant HTT (mHTT) 
[89]. Such very long repeat tracts might prevent downstream events that promote 
pathogenesis such as production of exon 1 fragments [11,90,91] or nucleo-cytoplasmic 
shuttling [92]. Landles et al. [93] demonstrated that a version of the R6/2 mouse with 90 
CAG, R6/2(CAG)90, showed earlier mHTT nuclear aggregation than an R6/2 line with 200 
CAG, R6/2(CAG)200, but later phenotype onset. The R6/2(CAG)90 brains contained nuclear 
aggregates that had a diffuse punctate appearance and remained partly detergent soluble, 
which correlated with the onset of transcriptional changes, whereas the R6/2(CAG)200 brains 
had cytoplasmic aggregates that gave larger inclusion bodies which correlated with 
behavioural changes. Both lines of mice showed somatic expansion of the CAG tract, 
therefore the exact CAG tract length giving rise to these different molecular sequelae 
remains unknown. Further detailed studies in animals with less extreme repeat lengths such 
as this might well yield more insights into the pathogenic mechanism and threshold. 
 
A number of models, still encoding glutamine but using a mixed CAACAG rather than a pure 
CAG tract, can help to establish a window for a pathogenic repeat length. The mixed 
CAACAG stabilises the repeat tract [75], preventing germline and somatic expansion.  
 The BAC HD model with 97 glutamines encoded by a mixed CAACAG tract fulfils this criteria 
– the mixed CAACAG tract prevents both germline and somatic expansion in mice but is still 
 15 
pathogenic (Table 1) [75]. These mice have 5 copies of the transgene integrated into their 
genome and express the BAC HD HTT at higher than endogenous levels, estimated at three-
fold the level of transcript and 1.5 – 2-fold the level of protein. They also notably show 
functional deficits, but no HTT-positive inclusions, and the translated mHTT protein is largely 
full-length and mainly located in the cytoplasm [75]. Other sequelae of the mixed tract may 
exert effects unrelated to CAG expansion: the CAACAG tract is likely to form different DNA 
structures to pure CAG tracts and this may well affect transcription at the locus. Differential 
codon usage may further affect translation efficiency of HTT: CAG is used to encode 
glutamine three times as frequently as CAA in brain tissue [94].  
 
Given the BAC HD line with a stable tract of 97 glutamine-encoding codons has a phenotype 
[75] this sets an upper bound to the likely intracellular pathogenic length (Table 1). The 
HdhQ92 mouse with a human exon 1 pure CAG tract knocked into mouse Htt has a late 
behavioural phenotype and mHTT inclusions. This is one of the minority of HD mouse 
models that has been assessed systematically for the presence of somatic instability, which 
is seen especially in brain and liver [57,95,96]. This means that the CAG tract length 
associated with the intracellular pathogenic threshold in these mice is unknown. Similarly 
the HdhQ72 and HdhQ80 models show some mild phenotypes but also show substantial 
somatic instability, again with high levels of instability in the striatum, consistent with the 
HdhQ92 mice [27,64,69]. Other rodent lines with CAG tracts of less than 100 repeats might 
provide further clarification. However, in most of these somatic expansion is likely to occur 
– though it has not been reported – as a human HTT transgene with a long pure CAG tract 
was used to generate these mice (Table 1) [51,55,60,70,71,97]. If expansion is occurring, in 
the germline or somatically, it is likely this will provoke changes in phenotype within a 
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cohort. More interesting are the models reported by Levine et al. (1999) with 71 and 94 
CAGs.  Both have a (coding) interruption in the middle of the CAG tract [61]. The 71 CAG 
mice have no reported abnormal behaviour and the 94 CAG mice only some minor changes 
[61]. Given the interruption in the CAG array of the transgene it is likely that somatic 
expansion is attenuated in these mouse models.  These animal models may well be either 
side of a threshold that defines pathogenesis, so it would be useful to investigate whether 
they display somatic expansion. 
 
There are additional limitations in extrapolation from mice and other animal models to 
people [98]. Expression levels of the gene and protein are not necessarily at endogenous 
levels. Genetically the most accurate animal models are those with long CAGs knocked into 
their mouse Htt gene (Table1). Most contain a human exon1/mouse Htt chimeric sequence 
which has the disadvantage of not being a gene that appears in nature at all. There is an 
allelic series where only the mouse CAGCAA sequence encoding 7 glutamines is replaced in 
mouse exon 1 [99] (Table 1), but this may not show appropriate human-relevant 
downstream pathogenic events. Animals are not humans and have inherent limitations such 
as short lifespans and differences in underlying biology, seen in DNA repair systems and 
oxidative damage [100], that may well be important in determining the pathogenic 
threshold in particular models.  
 
While both people with HD and the animal models of disease have development of 
phenotypic changes over time, animals do not have an age at onset of manifest disease, as 
at clinical diagnosis in humans. In both people and models the changes seen depend on 
what phenotypes are examined and how they are measured [36,101,102]. The differences 
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in disease manifestation in people are not reflected in mice, because laboratory mice are 
much less genetically diverse and live in a more uniform environment. Genetic variation in 
HD subjects influences the presentation of many non-motor symptoms for instance [103]. 
Most HD mouse models, despite possession of a repeat length that would give juvenile HD 
with its different clinical presentation, show a similar motor phenotype (though this may be 
an artefact of how this is measured (Table 1)) [44]. They also display very little frank 
neurodegeneration, though they often have smaller and lighter brains than their wildtype 
counterparts [43]. A series of matched knock-in lines with identical glutamine encoding 
stretches in Htt have been generated: one with pure CAG tracts and a parallel line with 
CAACAG alternating tracts [48]. These lines encode 45, 80 and 105 glutamines and should 
reveal the pathogenic threshold in mice provided expression levels are similar in the parallel 
lines, though the processing of mHtt may still be different in the mouse gene from the 
human gene. If extrapolating the pathogenic repeat threshold from mouse models is 
difficult, is it then possible to garner more relevant information from other human diseases 
caused by similar repeat expansions? 
 
Evidence from other diseases  
Repeat sequences are common in the genome and biologically functional [104] and there is 
a growing list of diseases caused by expanded repeated sequences in DNA [1,2,105]. A 
series of neurodegenerative diseases are caused by expanded CAG sections in their coding 
sequence, invariably translated to a polyglutamine tract [106]. These diseases have some 
striking similarities: the repeat threshold at which disease is caused is in most cases a similar 
length [4,45], they show a strong relationship of repeat length with age at onset of disease, 
many show somatic and germline expansion of their causative repeat [30,45,107–109] and 
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they have similar genetic modifiers of their ages at onset [110] (Table 2). This implies that 
the underlying events leading to expansion of the CAG tracts in these diseases might have 
common mechanisms that can be used to inform all of these diseases, though the molecular 
pathogenic events downstream of the CAG tract may be specific to each disease.    
 
Table 2 shows the diseases caused by expanded CAG tracts where the repeat is definitely or 
likely to be translated to a polyglutamine tract in the cognate protein – it is perhaps of 
relevance that most of the polyglutamine protein products have a role in DNA repair 
[31,106,111]. Only spinocerebellar ataxia 6 (SCA6, OMIM 183086) shows no evidence of 
somatic expansion of the CAG tract, though there is genetic anticipation in families, 
implicating germline expansion [112–114]. SCA6 may therefore be an exception, not 
requiring intracellular somatic expansion to elicit pathogenesis. The CAG tract disease range 
is shorter than in the other diseases, and the repeat occurs in CACNA1A, encoding a calcium 
channel. Nuclear inclusions are seldom observed [115–117] – and as in SCA2 (OMIM 
183090), are mainly cytoplasmic – thus it is likely that the cell toxicity in this disease is 
mediated through other, protein-based, mechanisms [118]. SCA7 (OMIM 164500), SCA12 
(OMIM 604326), dentatorubral-pallidoluysian atrophy (DRPLA, OMIM 125370) and spinal 
and bulbar muscular atrophy (SBMA, OMIM 313200) show no repeat tract interruptions and 
all have at least some evidence of somatic expansion (Table 2). Interruptions are present in 
the CAG tracts of the causative genes for SCA1 (OMIM 164400), SCA2 (OMIM 183090), SCA3 
(also known as Machado-Joseph’s disease, OMIM 109150), and SCA17 (OMIM 607136), 
though loss of interruptions is associated with disease-causing alleles in SCA2. These 
diseases are perhaps most informative in our quest to define the pathogenic CAG length 
range, as interruptions are known to stabilise expanded tracts, such that the inherited allele 
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repeat length is likely to be the maintained in most cells. Information on the extent to which 
interruptions reduce the rate of expansion and delay age at onset could be used to modify 
the Kaplan model and thus improve the estimate of the pathogenic threshold. 
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Table 2 Evidence from human CAG-repeat disorders 
 
Disease  
Normal 
CAG range 
Disease 
CAG range 
Pure repeat length/interruptions Phenotype Somatic expansion observed? References 
HD 6-35 36-200+ 
 
(CAG)n(CAA)(CAG) 
 
CAG tract usually ends CAACAG. Alleles without CAA or 
with multiple CAAs observed.  
  
Age at onset 2-80 years (n = 40 
years). 
Pure CAG alleles give earlier onset, 
multiple CAA interruptions later 
onset. 
Yes, in neural and peripheral tissues. 
More CAG expansion in brain, 
especially striatum, globus pallidus 
and cerebral cortex, than peripheral 
tissues (except the cerebellar cortex). 
Repeat expansion is greater in 
neurons than glial cells.  
[7,8,23,25–
28,119] 
SCA1 6-35  
39+ (no CAT) 
45-81+ 
 
(CAG)n(CAT)(CAG)n 
OR 
(CAG)n(CAT)(CAG)(CAT)(CAG)n 
 
CAG tract is usually interrupted by CAT or CATCAGCAT. 
Alleles without interruptions or with additional CATs 
observed. 
 
Age at onset 4-74 years (n = 40 
years). 
Pure CAG alleles give earlier onset, 
CAT interruptions later onset. 
Yes, in neural and peripheral tissues. 
More CAG expansion in brain than 
the peripheral tissues (except the 
cerebellar cortex). 
[113,120–
133] 
SCA2 14-31 32-270+ 
 
(CAG)n(CAA)(CAG)n 
OR 
(CAG)n(CAA)(CAG)4(CAA)(CAG)n 
OR 
(CAG)n(CAA)(CAG)4(CAA)(CAG)4 (CAA)(CAG)n 
 
CAG tract is usually interrupted by 1-3 CAAs separated 
by 4x CAGs. Alleles with no CAA, or with no CAAs and a 
CCG or CCGCCG interruption have also been observed. 
 
Age at onset 1-66 years (n = 32 
years). 
Pure CAG alleles – ataxic phenotype, 
CAA interruptions – Parkinsonism 
(SCA2-P) or ALS phenotype. 
Lack of CAA plus a CCG or CCGCCG 
exclusively observed in disease 
alleles 
Yes, in blood.  
No evidence of somatic expansion 
has been found in alleles with 
interrupted repeats involved in SCA2-
P phenotype. 
[113,122,134–
147] 
SCA3 12-44 52-86+ 
 
(CAG)2(CAA)(AAG)(CAG)(CAA)(CAG)n(CGG) 
OR 
(CAG)2(CAA)(AAG)(CAG)(CAA)(CAG)n(GGG) 
 
CAG tract ends with either CGG or GGG and is usually 
interrupted by two CAAs and one AAG. Alleles with one 
less CAA have been observed. 
 
Age at onset 4-70 years (n = 36 
years). 
No relationship between repeat 
interruptions and phenotype. 3’ 
flank CGG rather than GGG is 
associated with disease 
Yes, in neural and peripheral tissues. 
More CAG expansion in brain than 
the peripheral tissues (except the 
cerebellar cortex).  
[113,128–
131,148–152] 
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SCA6 7-16 21-28+ 
 
(CAG)n 
 
No interruptions in disease or normal allele. 
 
Age at onset 19-71 years (n = 48 
years). 
No  [112–114] 
SCA7 7-35 34-460+ 
 
(CAG)n 
 
No interruptions in disease or normal allele. 
 
Age at onset 1-45 years (n = 20 
years). 
Yes, in blood, kidney, and skeletal 
muscle (limited studies) 
[113,153–
159] 
SCA12 7-32 55-78+ 
 
(CAG)n 
 
No interruptions in disease or normal allele. 
 
Age at onset 8-55 years (n = 33 
years). 
Yes, in blood (limited studies) 
[113,160–
162] 
SCA17 25-44 47-63+ 
 
(CAG)3(CAA)3(CAG)n(CAA)(CAG)(CAA) 
(CAG)n(CAA)(CAG) 
 
CAG tract typically begins with (CAG)3(CAA)3, ends with 
CAACAG and has a central CAACAGCAA interruption. 
Alleles without CAACAGCAA have been observed. 
 
Age at onset 3-75 years (n = 35 
years). 
Alleles without CAACAGCAA are 
associated with disease phenotype 
Yes, in blood (limited studies).   
Mosaicism and therefore mutation 
frequency in patients with pure CAG 
repeats (without the central 
CAACAGCAA) is 2-3 fold of those with 
CAA interruptions. 
[113,163,164] 
DRPLA 6-35 48-83+ 
(CAG)n 
 
No interruptions in disease or normal allele. 
Age at onset 1-69 years (n = 30 
years). 
Yes, in neural and peripheral tissues. 
More CAG expansion in the brain 
than the peripheral tissues (except 
the cerebellar cortex). Repeat 
expansion is greater in glial cells than 
neurons. In cerebellum Purkinje cells 
and cerebral neuronal cells show 
more expansion than cerebellar 
granule cells. 
[130,150,165–
170] 
SBMA 9-36 38-62+ 
(CAG)n 
 
No interruptions in disease or normal allele. 
Age at onset 14-75 years (n = 43 
years). 
Yes, in neural and peripheral tissues. 
Skeletal and cardiac muscle showed 
the most expansion whereas central 
nervous system tissues, liver and 
spleen showed the least. 
[119,171–
175] 
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SCA1 disease-causing expanded CAG tracts are 39 CAGs or more with no interruption, or 45-
81 with interruptions. Lack of interruptions gives earlier disease onset [132] and in 
uninterrupted alleles there is a strong length correlation with age at onset [124]. The 
interruptions are CAT, encoding histidine rather than glutamine, and the later onset of 
disease was assumed to be mediated by the resulting change in the protein [123], but it 
appears more likely to be mediated at the level of DNA by the somatic expansion widely 
seen in this disease [120,121,126,128–130,133,176]. The pathology of SCA1 is concentrated 
in the cerebellum with a characteristic early and severe degeneration of the Purkinje cells 
[4] although recent evidence shows that subjects have widespread degeneration in deep 
cerebellar structures and the brainstem as well as cerebral pathology [177]. In post-mortem 
SCA1 human brain, the highest levels of somatic expansion are not seen in the cerebellar 
regions and the Purkinje cells most affected in the disease [126], though at the end stage of 
disease the earliest affected cells may have been lost. Additionally, Purkinje cells are low in 
number compared with other cerebellar neurons [178], and thus rare, large expansions in 
these cells are likely to be underestimated when looking at whole cerebellar tissue. 
However, elegant work in mice has shown that it is likely to be protein interactions, 
particularly with capicua, that drive cell-specific intracellular pathogenesis in the Purkinje 
cells [179,180]. Nevertheless, somatic expansion may drive other pathogenic events in 
SCA1: a similar genetic modification signal was seen in SCA1 as in HD, implying that age at 
onset is at least partly modulated by similar events in both diseases [110]. 
 
SCA2 is more complicated. Most CAG tract alleles have CAA interruptions, but may also be 
interrupted by CCG, encoding glycine. Pure CAG tracts over 34 CAG cause the ataxic 
phenotype of SCA2 [5,47,142], but interrupted alleles in what would normally be considered 
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the long normal or low SCA2 range (see Table 2), give a Parkinsonian or amyotrophic lateral 
sclerosis phenotype [135,138,145,181]. No evidence of somatic expansion has been seen in 
the phenotypes associated with interruptions [146,147] but it is seen in SCA2 [137].  
 
SCA3 is perhaps the most interesting and informative of the SCAs with respect to the CAG 
length pathogenic threshold. Normal alleles may have repeat lengths up to 44 CAG, whereas 
disease-associated alleles range from 52-75 CAG, with most disease alleles harbouring 
repeat lengths of over 60 CAG (Table 2) [45]. There is a window where no repeat lengths 
have been reported between the normal and disease ranges in SCA3 as in DRPLA, SCA12 
and SCA17. The CAG tract is usually interrupted by two CAAs and there does not seem to be 
an association between the presence of interruptions and phenotype. Notably the somatic 
mosaicism observed is of the order of a few repeats even in the presence of CAG tracts of 
70-80, and expansions are more prevalent in peripheral tissues than in nervous tissue 
[150,151]. Though these analyses are in relatively few brains and do not use techniques that 
would reveal individual large expansions, nevertheless this appears to be a more stable CAG 
repeat tract than in HD or SCA1 for instance, especially given the CAG tract length. This 
provides a repeat tract length for neurodegeneration of a minimum of 60 CAG in SCA3.  
 
SCA17 is caused by an expanded mixed CAA/CAG tract in TBP. The normal repeat number in 
TBP is up to 40 CAG/CAA, reduced penetrance alleles have 41–48 repeats, and full 
penetrance alleles carry more than 48 CAG/CAA repeats. These interrupted repeats have a 
complex structure [182,183] (Table 2). SCA17 predominantly occurs in subjects who do not 
carry a central CAACAGCAA interrupting sequence. The instability of the expanded CAG 
repeat is dependent on repeat configuration, and CAA interruption is a limiting factor for 
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further CAG repeat expansion [163]. There is some germline instability, raising the 
possibility that there is some somatic expansion also occurring despite the non-pure CAG 
tract.  
 
There are limitations to extrapolating from other diseases. They have different pathologies 
and different susceptible cell types. Notably in most of these diseases regional pathology 
and somatic expansion are not correlated, but relatively few subjects have been analysed in 
anatomical detail and only one study conducted at the single cell level. This study, 
measuring somatic expansion in single cells in DRPLA, compared somatic mosaicism in 
cerebellar structures in early versus late onset patients [170]. Higher rates of expansion 
were more evident in late onset case than early onset cases, though this may well be a 
function of age [85,184]. The frequency of expansions was highest in glial cells, with Purkinje 
cells lower and granular cells lower again. Relative levels of expression of the cognate genes 
in the most susceptible cells are not known, but are assumed to underlie differential spatial 
pathogenesis [118,185], and transcription appears to be important in promoting somatic 
repeat tract length changes [82–84,186–189]. Finally, surviving cells that are examined in 
post-mortem human brain may be resistant to the ongoing toxicity mechanisms and 
therefore uninformative about the intracellular pathogenic repeat length threshold. 
 
Mouse models in other repeat disorders 
There are multiple mouse models of each non-HD polyglutamine repeat disorder, most of 
which have not had somatic expansion of the repeat surveyed systematically (Table 3). Most 
alleles were cloned from patients as transgenes or knocked into the endogenous mouse 
genes, and often required longer CAG repeat lengths than in humans to evoke a phenotype. 
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As in HD animal models, transgenic mouse models of these diseases often demonstrate 
severe early-onset neuropathology and behavioural syndromes whilst knock-in mouse 
models tend to show milder late-onset phenotypes that perhaps parallel the disease more 
accurately, but are slower to produce phenotypes. Consistent with animal models of HD, 
animal models of other triplet repeat disorders tend to show increased disease phenotype 
as CAG repeat length increases, though this is influenced by the promoter used, transgene 
copy number and resultant transgene expression. Cemal et al. [190] generated a series of 
eight YAC SCA3 models and found that disease severity increased both with an increased 
CAG repeat tract length and an increased transgene copy number such that an animal with 
72 CAG and one copy of the transgene developed symptoms later than an animal with 67 
CAG repeats and two copies of the transgene. 
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Table 3 Animal models in other repeat disorders 
 
Disease Animal model Construct Promoter 
PolyQ 
repeat 
length 
Pure repeat length/ 
interruptions 
Phenotype Somatic expansion observed? References 
DRPLA 
AT-FL-65Q 
FL human 
ATN1 
Prp Q65 (CAG)n 
Motor deficits from 9 weeks. NIIs 
from 19 weeks. 
Not reported [191,192] 
ATN-1[Q76] 
FL human 
ATN1 
ATN1 Q76 (CAG)n 
Motor deficits from 8 weeks. DNS 
from 14 weeks. 
Yes at 64 weeks. High levels of 
somatic expansion in cortex, 
liver, kidney. Low levels in 
cerebellum and heart. 
[193–195] 
Q96 
FL human 
ATN1 
ATN1 Q96 (CAG)n 
Motor deficits from 8 weeks. 
Decreased life span (54 weeks). 
Not reported [194] 
Q113 
FL human 
ATN1 
ATN1 Q113 (CAG)n 
Motor deficits from 7 weeks. 
Decreased life span from 21 weeks. 
Not reported [194] 
Atro-118Q 
FL human 
ATN1 
NSE Q118 (CAG)n 
Motor deficits from 5 weeks. DNS 
and NIIs from 12 weeks. Decreased 
lifespan from 14 weeks. 
Not reported [196] 
Tg(ATN1)Q12
9Stsu 
FL human 
ATN1 
ATN1 Q129 (CAG)n 
Motor deficits from 3 weeks. DNS 
from day 4. NIIs at 9 weeks. 
Decreased lifespan from 10 weeks. 
Somatic instability not reported. 
Germline ATN1 instability 
reported. 
[194,195,197] 
SCA1 
Sca178Q 
Chimeric 
human exon 
8/ mouse 
Atxn1 
Atxn1 Q78 (CAG)n 
Motor deficits from 9 months. No 
neuropathological changes up to 18 
months. 
Somatic instability not reported. 
Intergenerational repeat 
instability (+2 to -6 CAG) 
[198] 
PS-82 or B05 
FL human 
ATXN1 
Pcp2/L7 Q82 (CAG)n 
Motor deficits from 5 weeks. NIIs in 
Purkinje cells at 6 weeks. Purkinje 
cell loss 24 weeks. 
Not reported. 
Intergenerationally stable. 
[199–201] 
PrP-tTA/TRE-
SCA1 
FL human 
ATXN1 
Tet-Prp Q100 (CAG)n 
Motor deficits from 5 weeks. 
Purkinje cell loss, dendritic 
degeneration and reactive gliosis 
from 20 weeks 
Not reported [202] 
Sca1154Q 
Chimeric 
human exon 
8/ mouse 
Atxn1 
Atxn1 Q154 (CAG)n 
Motor deficits from 8 weeks. NIIs in 
hippocampus and cerebral cortex 
from 7 weeks. NIIs in cerebellum at 
40 weeks. 
Yes, observed in most tissues at 
40 weeks. Considerable 
expansions in striatum (> 210 
CAG), spinal cord and pons. 
[203,204] 
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SCA2 
Atxn2-CAG42-
Knock-In 
Expanded 
CAG in exon 2 
of mouse 
Atxn2 
Atxn2 Q42 (CAG)n 
Motor deficit from 18 months. DCS 
and CI in cerebellum at 13 months. 
No somatic instability or 
intergenerational instability. 
[205] 
58Q-5B 
FL human 
ATXN2 
Pcp2/L7 Q58 (CAG)n 
Motor deficits from 16 weeks. CIs 
and decreased number of Purkinje 
cells at 24 weeks. 
Not reported [206,207] 
BAC-Q72 
FL human 
ATXN2 
Atxn2 Q72 (CAG)n 
Motor deficits from 8 weeks. 
Morphological changes in Purkinje 
cells at 24 weeks. 
Not reported [208] 
75Q-SCA2 
FL human 
ATXN2 
Atxn2 Q75 (CAG)n 
Motor deficits from 6 weeks. 
Purkinje cell degeneration from 52 
weeks 
Not reported. 
Intergenerationally stable. 
[209] 
Atxn2-
CAG100-KIN 
Expanded 
CAG in exon 2 
of mouse 
Atxn2 
Atxn2 Q100 (CAG)n 
Motor deficits from 20 weeks. 
Progressive brain atrophy and 
neuronal aggregation in multiple 
brain regions from 13 weeks. 
Yes, expansions > 128 CAG 
observed. Somatic mosaicism 
observed in multiple mice. 
[210] 
ATXN2[Q127] 
FL human 
ATXN2 
Pcp2/L7 Q127 (CAG)n 
Motor deficits from 8 weeks. 
Extranuclear aggregates and DCS in 
the cerebellum from 4 weeks.  
Purkinje cell loss from 12 weeks. 
Not reported [211] 
SCA3 
MJD 64.8 
FL human 
ATXN3 
ATXN3 Q64 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)58 
Motor deficits from 3 weeks. Severe 
neuronal loss and gliosis. 
Widespread NIIs from 5 months. 
Not reported [190] 
MJD67.2 
FL human 
ATXN3 
ATXN3 Q67 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)61 
Motor deficits from 4 weeks. NIIs in 
multiple brain regions. 
Not reported [190] 
Pcp2/ATXN3_
69CAG 
c-terminus 
human 
ATXN3 
Pcp2/L7 Q69 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)63 
Motor deficits from 3 weeks. 
Cerebellar atrophy from 3 weeks. 
DCS in cerebellum at day 5, NIIs at 7 
weeks. 
Not reported [212] 
70.61 CAG 
FL human 
ATXN3 
Prp Q70 Not reported 
Motor deficits from 12 weeks. 
Widespread NIIs at 3-4 months 
Not reported [213,214] 
Q71B/C 
FL human 
ATXN3 
Prp Q71 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)65 
Motor deficits from 11 weeks. 
Widespread NIIs at 2-3 months 
Not reported [215] 
MJD72.1 
FL human 
ATXN3 
ATXN3 Q72 (CAG)4(CAA)(CAG)67 
Motor deficits from 34 weeks. NIIs in 
10% pontine and dentate neurons 
Not reported [190] 
MJD76.1 
(founder) 
FL human 
ATXN3 
ATXN3 Q76 (CAG)2(CAA)(AAG) Motor deficits from 4 weeks. Not reported [190] 
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(CAG)(CAA)(CAG)70 
PrP/MJD77-
het/hom 
FL human 
ATXN3 
Tet-Prp Q77 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)72 
Motor deficits from 9 weeks. NIIs in 
cerebral cortex at 4 weeks. 
Not reported [216] 
HA-Q79 
FL human 
ATXN3 
Pcp2/L7 Q79 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)n 
No behavioural phenotype or 
neurological phenotype at 23 weeks 
Not reported [217] 
HA-Q79 
Truncated 
ATXN3 
Pcp2/L7 Q79 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)n 
Ataxia from 4 weeks, failed to rear   
Reported as stable on 
transmission. 
[217] 
Ataxin-3-
Q79HA 
FL human 
ATXN3 
Prp Q79 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)n 
Motor deficits from 20 weeks. 
Widespread NIIs at 43 weeks. 
Not reported [218] 
Atxn3Q82/Q6 
Chimeric 
human exon 
10/ mouse 
Atxn3 
ATXN3 Q86 
(CAG)2(CAAAAG) 
(CAG)82 
No motor impairment at 52 weeks. 
NIIs in deep cerebellar nuclei at 10 
weeks. Extranuclear inclusions in 
striatum, hippocampus. 
Somatic instability not reported 
but intergenerational instability 
observed 
[219] 
MJD84.2 
FL human 
ATXN3 (two 
copies) 
ATXN3 Q84 
CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)78 
Motor deficits from 4 weeks. 
Widespread DNS (52 weeks). NIIs 
cerebellum and pons. Purkinje cell 
loss (80 weeks). 
Not reported [190,220] 
MJD22.1/84.1 
FL human 
ATXN3 
ATXN3 Q84 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)12 
(CAA)(CAG)65 
Motor deficits not reported, mild 
neuronal loss and gliosis. NIIs in 
pontine and dentate. 
Not reported [190] 
Ki91 
Chimeric 
human exon 
7-11/ mouse 
Atxn3 
ATXN3 Q91 Not reported 
Motor deficits from 90 weeks. 
Cerebellar degeneration and mild 
loss of Purkinje cells from 52 weeks. 
Yes, age-dependent expansions 
prominent in the striatum, pons 
and testes at 40 weeks. 
Intergenerational instabilities 
also observed. 
[221] 
Hemi-
CMVMJD94 
FL human 
ATXN3 
CMV Q94 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)77 
Motor deficits from 16 weeks. Mild 
neuronal atrophy in pontine and 
dentate nuclei (16 weeks). No NIIs at 
12 months. 
Yes, age-dependent increase 
observed in multiple tissues. 
Pontine nuclei, substantia nigra, 
striatum and liver showed the 
highest rates. 
[222] 
CMVMJD135 
FL human 
ATXN3 
CMV Q135 
(CAG)2(CAA)(AAG) 
(CAG)(CAA)(CAG)129 
Motor deficits from 10 weeks. NIIs in 
pons and spinal cord from 20 weeks. 
Neuronal loss in the pons from 60 
weeks. 
Somatic mosaicism observed.  
Intergenerational instability in 
54-79% of transmissions. 
[223] 
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148.19 CAG 
FL human 
ATXN3 
Prp Q148 Not clear 
Motor deficits from 9 weeks. 
Widespread NIIs (3-4 months) 
Not reported [214] 
HDPromMJD1
48 
FL human 
ATXN3 
Htt Q148 Not clear 
Motor deficits from 57 weeks. NIIs in 
red nucleus, pons and the 
cerebellum from 78 weeks. 
Intergenerational instability [224] 
SCA3-KI 
Expanded 
CAG in exon 
10 of mouse 
Atxn3 
ATXN3 Q304 (CAACAGCAG)n 
Motor deficits and widespread NIIs 
from 18 months 
Not reported [225] 
SCA6 
CT-longQ27PC 
FL human 
CACNA1A 
CMV/ ACTB Q27 (CAG)n 
Motor deficit from 8 months. 
Purkinje cell degeneration. 
Not reported [226] 
Cav2.1 knock-
in mice 
  
Insertion of 
CAG into 
exon 47 
CACNA1A Q28 (CAG)n Motor deficits from 6 months Not reported [227] 
SCA6_30Q 
Chimeric 
human exon 
47/ mouse 
Cacna1a 
CACNA1A Q30 (CAG)n No motor impairment Not reported [228] 
SCA6_84Q 
Chimeric 
human exon 
47/ mouse 
Cacna1a 
CACNA1A Q84 (CAG)n 
Motor deficits from 30 weeks. NIIs in 
Purkinje cells at 22 months. 
Not reported [228,229] 
MPI-118Q 
Chimeric 
exon 47 with 
splicing site 
mutation 
CACNA1A Q118 4 CAA interruptions 
Motor deficits from 6 weeks. 
Purkinje cell number decrease from 
6 weeks and cytoplasmic inclusions 
from 7 weeks. 
Not reported [230] 
SCA7 
ataxin-7-Q52 
FL human 
ATXN7 
PDGF-B Q52 (CAG)n 
Motor deficits from 7 months. DNS 
at 39 weeks, NIIs in cerebellum from 
43 weeks 
Not reported [231,232]  
P7E 
FL human 
ATXN7 
Pcp2 Q90 (CAG)n 
Motor deficits from 48 weeks. DNS 
in Purkinje cells from 3 weeks and 
NIIs from 35 weeks 
Not reported [233] 
R7E 
FL human 
ATXN7 
Rhodopsin Q90 (CAG)n 
No motor deficits reported. DNS in 
eye retina from 2 weeks and DCS 
from 4 weeks 
Not reported [233,234]  
PrP-SCA7-
c92Q 
FL human 
ATXN7 
Prp Q92 (CAG)n 
Motor deficits from 8 weeks. NIIs in 
photoreceptors (11 weeks) and in 
the pons, hippocampus and medulla 
(19 weeks). 
Yes, mild somatic mosaicism 
(100 CAGs). 
[235–237]  
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Gfa2-SCA7-
92Q 
FL human 
ATXN7 
GFAP (Gfa2) Q92 (CAG)n 
Motor deficits from 34 weeks. 
Reactive gliosis, dendritic 
degeneration (39 weeks), DNS and 
DCS in cerebellum (52 weeks) 
Not reported [238] 
PrP-floxed-
SCA7-92Q 
BAC 
FL human 
ATXN7 
Prp Q92 (CAG)n 
Motor deficits from 21 weeks. Loss 
of cells in molecular layer and los of 
glial processes (40 weeks) 
Not reported [239] 
Atxn7 100Q 
Chimeric 
human exon 
3/ mouse 
Atxn7 
Atxn7 Q100 (CAG)n 
Cerebellar molecular layer atrophy 
at 8-9 months. 
Not reported [240] 
B7E2 
FL human 
ATXN7 
PDGF-B Q128 (CAG)n 
Motor deficits from 22 weeks. DCS 
in cerebellum and cerebral cortex (4 
weeks), DNS (9 weeks) and NIIs (17 
weeks). 
Not reported [241] 
Sca7 266Q/5Q 
Chimeric 
human exon 
3/ mouse 
Atxn7 
Atxn7 Q266 (CAG)n 
Motor deficits from 5 weeks. 
Widespread NIIs from 5 weeks. Brain 
volume decrease, apoptosis 
increase, cell loss from 12-15 weeks. 
Not reported. Intergenerational 
instability reported. 
[242] 
SCA17 
TBPQ64 (rat) FL human TBP Prp Q64 64 mixed CAA/CAG 
Motor deficits from 3.5 months. 
Degeneration of Purkinje cell layers 
at 9 months. 
Not reported. Intergenerational 
stability across three 
generations 
[243] 
TBP-71Q-27 FL human TBP Prp Q71 71 mixed CAA/CAG 
Motor deficits from 6 weeks. DNS in 
multiple brain regions from 15 
weeks. Purkinje cell degeneration. 
Not reported [244] 
TBP-105Q FL human TBP Prp Q105 105 mixed CAA/CAG 
Motor deficits from 6 weeks. NIIs in 
cerebellum from 10 weeks. 
Not reported [244] 
L7-hTBP FL human TBP Pcp2/L7 Q109 109 mixed CAA/CAG 
Motor deficits from 9 weeks. 
Purkinje cell loss (4 weeks). DNS in 
brainstem, cerebellum, cerebral 
cortex and striatum (22 weeks). 
Not reported [245] 
SBMA 
Mx-AR FL human AR Mx Q45 (CAG)n No behavioural phenotype. 
Somatic instability not reported. 
No change in repeat across 4 
generations. 
[246] 
NSE-AR FL human AR NSE Q45 (CAG)n No behavioural phenotype. 
Somatic instability not reported. 
No change in repeat across 4 
generations. 
[246] 
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FL (full length), Prp (prion protein), NSE (neuron specific enolase), NIIs (neuronal intranuclear inclusions), DCS (diffuse cerebellar staining), DNS 
(diffuse nuclear staining), CI (cerebellar inclusions) 
 
 
 
AR YAC CAG 
45 
450-kb YAC 
construct 
with 100-kb 
human AR 
gene 
AR Q45 (CAG)n No behavioural phenotype. 
No somatic instability. 
Intergenerational repeat 
instability in 10% of 
transmissions. 
[247] 
AR48Q 
Chimeric 
human exon 
1/ mouse Ar 
mAR Q48 (CAG)n 
No behavioural phenotype at 23 
months. Gene expression alteration 
in testes at 26 weeks. 
Not reported [248] 
AR65 FL human AR CMV Q65 (CAG)n Motor deficits from 16 weeks. Not reported [249] 
AR-97Q FL human AR 
Chicken β-
actin 
97 (CAG)n 
Motor deficits from 9 weeks. 
Widespread DNS and NIIs from 15 
weeks 
Not reported [250] 
AR100 FL human AR hAR 100 (CAG)n 
Motor deficits in males at 48 weeks. 
NIIs and DNS in spinal cord and 
hypothalamus (61 weeks). 
Not reported [251] 
112Q FL human AR Prp 112 (CAG)n 
Motor deficits from 6 weeks. NIIs in 
spinal cord (6 weeks) 
Not reported [252] 
AR113Q 
Chimeric 
human exon 
1/ mouse Ar 
mAR 113 (CAG)n 
Motor deficits from 8 weeks. NIIs in 
skeletal muscle (10 weeks). Reduced 
fertility. 
Not reported [253,254] 
AR120 FL human AR CMV 120Q (CAG)n 
Motor deficits from 3 weeks. Cell 
loss in the spinal cord from 13 
weeks, brain volume decreases from 
26 weeks 
Not reported [249] 
AR239Q FL human AR hAR 239Q (CAG)n 
Motor deficits from 4 weeks.  
Widespread NIIs (8 weeks). 
Somatic instability not reported. 
Minor intergenerational 
instability. 
[255] 
 32 
In some cases, allelic series have been ‘naturally’ generated through intergenerational 
expansions or contractions following extensive breeding [193–195,222]. These models allow 
us to explore the effect of CAG repeat length in a well-controlled system. One such system is 
a series of transgenic DRPLA mouse models carrying 76, 96, 113 and 129 CAG, whose motor 
deficits and cognition worsen with CAG repeat length and age. High levels of somatic 
expansion were observed in the cortex, liver and kidney of the Q76 mice [193], and 
although no behavioural phenotype was initially reported in the Q76 after 64 weeks, they 
showed reduced survival and body weight when compared with non-transgenic littermates 
[194] as well as neuronal intranuclear accumulation [193]. Again, repeat instability is likely 
to occur in all models, but was only examined in Q76 animals.  
 
Genomic context is an important driver of repeat instability in these models. Early studies of 
independent transgenic mouse models of SBMA with 45 AR CAG repeats revealed no 
behavioural phenotype at this repeat length, but did highlight the importance of genomic 
context in mediating intergenerational repeat instability in mice possessing repeats at the 
lower end of the pathogenic range [246,247]. Consistent with this, a knock-in mouse model 
of SBMA with 48 AR CAG repeats demonstrated no overt behavioural phenotype at 23 
months but did show changes in gene expression. Genomic context also appears to govern 
intergenerational and somatic expansion in a mouse model of SCA7 [237]. 
 
Marked repeat instability has been observed in a transgenic mouse model of SCA3, 
CMVMJD94, which carries 94 CAG repeats [222]. Expansion was observed in multiple 
tissues, but within the brain mosaicism was most notable in the pontine nuclei, substantia 
nigra and striatum. Somatic instability correlated well with neuronal atrophy and gliosis in 
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the pontine nuclei and substantia nigra, but pathological involvement was not seen in the 
striatum [222]. Another mouse model of SCA3, Ki91, and a mouse model of SCA1, 
Sca1154Q/2Q, also demonstrate similar tissue-specific patterns of repeat expansions, with 
notable expansions in the striatum [204,221]. This extends to other repeats – the same 
tissue distribution of expansion is seen in models of myotonic dystrophy [184]. These data 
suggest that whilst repeat instability is not associated with cerebellar neuronal vulnerability 
in models of SCA, it is likely that repeat instability in areas other than the cerebellum might 
contribute to disease pathogenesis [256]. Intergenerational instability has been observed in 
numerous models of SCA3 despite the interrupted CAG tract; this could be due to the 
presence of a long uninterrupted stretch of CAG at the 3’ end of the tract 
[219,221,223,224]. These findings suggest that somatic instability is occurring in these 
model systems.  
 
Some models have allowed us to examine the substantial effect that inheriting only 1 or 2 
CAG additional repeats may have on phenotype [222]. SCA3 mice with 83 CAG repeats did 
not demonstrate behavioural differences, yet SCA3 mice with 94 CAG repeats and similar 
expression levels demonstrated rotarod deficits and behavioural abnormalities from 16 
weeks. It was concluded that the threshold for disease in this model was between 84-94 
CAG repeats. Analysis of data from two cohorts of Q94 also revealed an inverse correlation 
between the length of the CAG repeat tract and the time spent on the rotarod [222].  
 
Whilst animal models have been invaluable in examining pathogenesis in these diseases, as 
in HD models, to date, it has been difficult to show directly that somatic expansions are 
causative to neuronal dysfunction, earlier age at onset and faster disease progression. 
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Interpretation of results is difficult when repeat sequence and length are not clearly defined 
or have not been examined. Many of the issues that arise in the HD animal models also arise 
in animal models of other repeat disorders and for many of the same reasons.  However, 
the conclusion from human CAG repeat disorders, and also the corresponding mouse 
models, would indicate that a repeat length of less than 100 CAGs is toxic to cells – at the 
shorter end of that estimated by Kaplan et al. [32]. Exactly where the intracellular 
pathogenic threshold falls remains unclear, but the evidence would place it at over 60 CAG. 
The question remains whether it is possible to define the intracellular pathogenic threshold 
more accurately. 
 
What evidence do we need to refine our definition of the intracellular pathogenic 
threshold?  
The parameters used to establish the CAG-length threshold for HD pathogenesis by Kaplan 
et al. [32] included the CAG size threshold for disease to arise, the subject’s inherited repeat 
length as measured in blood, and their current age: these data are available. However, they 
also require a measure of the cell group critical portion – of the most susceptible cell 
population(s), what proportion have died, or are dysfunctional, at onset of clinical disease? 
The final unknown, for HD and the other repeat diseases, is the basal expansion rate of the 
repeat over time. In HD, the cell group critical portion can be estimated from previous work 
that showed around half of the most susceptible D2R-expressing medium spiny neurons in 
the striatum have been lost at onset [257–259]. This parameter could likely be estimated in 
living subjects from imaging data, as recent well-standardised structural imaging and clinical 
data has been collected in prospective studies in both manifest and premanifest subjects 
[36,260].  
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The basal expansion rate of the repeat in the most susceptible cells is much more difficult to 
measure or to derive from existing data. Given the likely stochastic nature of the allele 
expansion process and the data available in human brain which indicates very long repeats 
in some cells [23], this will be hard to estimate. However, the very long repeats could be 
rare events and indeed, could be protective in those surviving cells, as such repeat lengths 
are seen to reduce phenotype severity and delay onset in mice [87]. The most useful data 
are likely to come from single cell approaches in a combination of human and mouse brain. 
It would be ideal if all the data we needed could be derived from human brain, but this is 
unlikely to be sufficient as human post-mortem brain is at the end stage of disease, and the 
only cells that can be surveyed are those that have survived. These are likely not 
representative of those that died earlier, and they may well themselves have been 
dysfunctional at death. Nevertheless, given this is likely a stochastic process there might be 
surviving cells at different points in the pathological trajectory that could be used in single 
cell experiments to define the pathogenic CAG tract length threshold. There are methods to 
sequence and size the HTT CAG tract accurately [261,262], which could potentially be 
applied to single cells, but these would have to be tied to the single cell RNA gene 
expression data – achievable, but technically challenging. 
 
Mouse brain is likely to offer a clearer picture of the dynamics of the pathological process, 
as tissues can be taken across the lifespan of the mouse and can be processed immediately 
to generate high quality single cell data. One major disadvantage of most HD mouse models 
is that they show little frank neurodegeneration, and in this respect do not recapitulate the 
human disease, but rather display neuronal dysfunction. However, for some analyses this is 
an advantage. Current data indicates that HD cellular dysfunction can be measured by single 
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cell RNA-seq [263–265] – though the disconnect between behavioural and gene expression 
changes observed by Landles et al. [93] may make this difficult to interpret. The barrier here 
is gaining a measure of HTT CAG tract length in individual cells and matching that up with 
the gene expression signature of the same cells – the same technical challenge as noted 
above in human brain but perhaps easier to overcome in mouse brain. Single cell studies in 
mouse brain would also be a way to answer a long-standing question in HD: do vulnerable 
neurons die because of intracellular pathological events induced by the CAG tract, as we 
argue here, or do they die because of aberrant intercellular events, or both [266–268]? In 
addition, mice with a shorter repeat length than those currently widely used in HD research 
will be necessary to examine the intracellular pathogenic threshold as they will need to start 
with a repeat length below that threshold. Another advantage of mice is that blood and 
brain somatic instability can be directly correlated. If this relationship can be established 
then it may be possible to extrapolate to human subjects where only blood is available.  
 
Using the age at onset genetic modifier data obtained in people might help to establish the 
pathogenic threshold. The effect sizes and directions of the known modifiers can be used to 
construct a polygenic risk score, which here consists of the sum of all known modifier 
alleles, weighted by the effect of each allele on onset [269].  This score can be used to 
predict somatic expansion in individuals without requiring expansion to be measured 
directly, thereby greatly increasing sample size, and may be incorporated into the Kaplan 
model [32]. This assumes that age at onset is a surrogate for measuring somatic expansion: 
Ciosi et al. [6] showed that individuals with higher blood DNA HTT CAG expansion have 
earlier HD onset and that the level of expansion in blood was associated with variants in 
selected genome-wide significant DNA repair genes from the modifier GWAS [7]. The 
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question then becomes what is the relationship between blood DNA HTT CAG expansion 
and brain DNA HTT CAG expansion? Again, mice will be the model best able to test this 
directly. It would also be useful to have a prospective study of somatic expansion in blood in 
manifest and premanifest carriers to investigate how expansion increases over time and 
with proximity to onset: this could be performed in TRACK and TRACK-ON [36,270] though 
studies of longer duration might be needed to establish longitudinal trajectories of repeat 
length. Then, if the relationship between expansion in blood and brain can be established 
experimentally, these trajectories may help infer the pathogenic HTT CAG threshold in the 
most susceptible cell populations in brain. As larger genetic studies are performed in HD the 
various polygenic risk scores will become more accurate and account for more phenotypic 
variation. In particular, risk scores estimating somatic expansion directly will be important in 
improving inferences about the pathogenic CAG length threshold via the Kaplan model.  This 
will require genome-wide association studies of somatic expansion with large sample sizes.  
 
Given the recent interest in targeting somatic expansion of the expanded CAG in HTT, it 
behoves us to understand just how much of that expansion we need to prevent in order to 
substantially delay onset and slow the progression of disease. Evidence from animal models 
of HD and from other diseases caused by expanded CAG tracts place the threshold for 
cellular dysfunction above 60 CAG but below 100 CAG. Modelling in blood gives an 
expansion parameter that predicts age at onset [6] and this may prove a useful biomarker 
especially in clinical trials that target somatic expansion. While the prediction works well at 
a population level it is not currently clinically useful for individuals. There are substantial 
differences between individuals that could well be improved by using other peripheral 
tissues to measure expansion or by improving the model using genetics. As a first step, the 
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CAG length and sequence themselves need to be more accurately measured (Hong et al. 
and Ciosi et al., this issue). It should further be borne in mind that there are likely to be 
different repeat length dynamics in different cell types and the nature of the rate of 
expansion in different cell types is unknown. Cellular toxicity may be driven by different 
mechanisms in different cell types and different diseases. Specifically, in HD, in order to 
improve power in clinical trials, it would be very helpful to know how the HTT CAG 
expansion measured in blood relates to expansions in specific vulnerable cell types in the 
brain, and what influences that relationship. This might allow us to increase the power and 
shorten clinical trials by using a model that includes blood or other peripheral tissue HTT 
CAG expansion data, genetic data and imaging data. This could speed up getting treatments 
to the clinic (Benn et al., this issue).  
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